|
Jul 15
|
3 Promising Penny Stocks With Market Caps Under $200M
|
|
Jun 30
|
Pliant halts bexotegrast development for IPF after trial results
|
|
Jun 27
|
Pliant Therapeutics Provides Update on BEACON-IPF
|
|
Apr 10
|
PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know
|
|
Apr 7
|
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
|
|
Mar 14
|
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’
|
|
Mar 13
|
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
|
|
Feb 18
|
Blade Air Mobility Leads The Charge Among 3 US Penny Stocks
|
|
Feb 14
|
All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to Buy
|
|
Feb 13
|
Pliant Therapeutics to Assemble Expert Panel to Review BEACON-IPF Trial Data; Shares Jump
|
|
Feb 13
|
Neumora shakes up its C-suite; Biogen cuts early-stage pipeline
|
|
Feb 13
|
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
|
|
Feb 11
|
Pliant Therapeutics downgraded to Neutral from Overweight at JPMorgan
|
|
Feb 10
|
Pliant Therapeutics Pauses Enrollment in BEACON-IPF Trial, Shares Take Steep Dive
|
|
Feb 10
|
Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues
|
|
Feb 10
|
Pliant shares collapse as company halts fibrosis drug study
|
|
Jan 2
|
Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Oct 5
|
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc
|
|
Oct 1
|
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
|
|
Sep 30
|
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|